Methods of treating obesity
By using the composition of GPR84 and GPR120 agonist, enteroendocrine cells are activated, and the problems of insufficient food intake and low compliance in existing obesity treatment methods are solved, efficient obesity and overweight treatment is achieved, and oral treatment is achieved. The convenience of administration.
Patent Information
- Application Number
- CN202411244052.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2016-07-19
- Filing Date
- 2017-03-15
- Publication Date
- 2024-11-08
AI Technical Summary
Existing obesity treatments have problems with insufficient food intake, poor taste, low compliance and difficulty in effectively stimulating enteroendocrine cells, and technology based on targeted release formulations has not been successfully used to treat obesity and type II diabetes.
A composition is provided, comprising a GPR84 agonist and a GPR120 agonist, including medium-chain free fatty acids and omega-3 fatty acids and esters thereof, to increase the release of intestinal hormones by activating enteroendocrine cells, for the treatment of obesity and overweight.
The composition can effectively increase the activation of enteroendocrine cells, maximize satiety, provide a safe and effective method to treat obesity and overweight, and can be administered orally, with high compliance and convenience.
Smart Images

Figure HDA0005030107780000011 
Figure HDA0005030107780000012 
Figure HDA0005030107780000021
Abstract
Description
[0001] Related Applications
[0002] The present invention is a divisional application of a patent application filed on November 15, 2018, with application number 2017800302573 and titled “Method for treating obesity”. Technical Field
[0003] The present invention relates to methods of treating obesity. Compositions useful for treating obesity and related disorders are also described. Background Art
[0004] Obesity and overweight are some of the major health challenges facing modern medicine and society. In 2016, the World Health Organization defined the shared health consequences of overweight and obesity as: cardiovascular disease (primarily heart disease and stroke), which was the leading cause of death in 2012; diabetes; musculoskeletal diseases (particularly osteoarthritis); and some cancers (endometrial, breast, and colon).
[0005] Bypass surgery is an effective treatment for obesity and type II diabetes. It works by shunting the ingested food directly to the lower part of the intestine, so that the nutrients that are not absorbed stimulate the intestinal lining cells to release intestinal hormones. These hormones relieve hunger in the brain, and they simultaneously stimulate the pancreas to produce insulin (Bueter & le Roux Int JObes (Lond) 35 Suppl 3: S35-9 (2011)). Exactly which nutrients cause this effect, and which hormones they release, and how to release are not fully understood.
[0006] Current protein-based weight loss methods use large oral loads that contain significant caloric value. They stimulate only a portion of the system and are mostly or completely absorbed before reaching the lower intestine. Therefore, the reduction in food intake is minimal and the formulation must be prepared by the subject making it inconvenient. Also, the taste is poor and compliance is low.
[0007] Other weight loss therapies include lipase inhibitors (eg ) and protein shakes (e.g. There is also synthetic pancreatic polypeptide being developed for subcutaneous treatment ((Tan et al. Br J Clin Pharmacol 2012; 73:232-9)).
[0008] Targeted release formulations for drugs delivered to the intestinal lumen are available. Recent developments now allow them to be specifically released in the large intestine (Varum et al Eur J Pharm Biopharm. 84 (3): 573-7 (2013)). To date, these formulations have been designed to deliver anti-inflammatory drugs for the treatment of inflammatory bowel disease (Vieira et al Carbohydr Polym. 93: 512-7 (2013)). However, there is growing interest in using this technology for delivering nutrients known to activate enteroendocrine cells to treat obesity 3 (Chambers et al Gut 64 (11): 1744-54 (2015) and doi: 10.1136 / gutjnl-2014-307913. Epub 2014 Dec 10) and type II diabetes (Ma et al Diabetologia 56: 1236-42 (2013)). Attempts to treat obesity in this way have not been successful so far.
[0009] When lauric acid (a component of coconut oil) is instilled into the small intestine via a nasogastric tube, it reduces food intake more potently than other fatty acids (Feltrin et al Am J Physiol Regul Integr Comp Physiol 287:R524-33 (2004); Feltrin et al Am J Clin Nutr 87:1181-7 (2008)).
[0010] Lauric acid does this by increasing plasma levels of gut hormones such as peptide YY (PYY) and glucagon-like peptide-1 (GLP-1). Evidence suggests that a lauric acid receptor called GPR84 (Oh & Lagakos Curr Opin Clin Nutr Metab Care 14:322-7 (2011); Wang et al J Biol Chem 281:34457-64 (2006)) is localized on enteroendocrine cells containing serotonin and PYY / GLP-1 in the human intestine (Symonds et al. Gut 64:618-26 (2015)).
[0011] Lauric acid has also been shown to activate downstream signaling pathways in these cells involving phosphorylation of extracellular signal-related kinase (pERK), while other nutrients can activate the same cells, but not through pERK. In contrast, other nutrients activate pCalmodulin kinase II (pCAMKII), a pathway parallel to pERK. One such nutrient is α-linolenic acid (a component of linseed oil), which acts through a specific receptor, GPR120. GPR120 knockout mice are obese, so there is great interest in using this receptor to treat obesity (Ichimura et al Nature 483:350-4 (2012); Ulven & Christiansen Annu. Rev. Nutr., 35, 239-263 (2015)) or diabetes (Hirasawa et al Nature Medicine, 11 (1), 90-94 (2005)).
[0012] Therefore, there is a need for a safe and effective treatment for obesity and overweight. Summary of the invention
[0013] According to a first aspect of the present invention, a composition for treating obesity and overweight is provided, the composition comprising a GPR84 agonist and a GPR120 agonist. The GPR84 agonist and GPR120 agonist mentioned include variants and derivatives thereof. When the GPR84 agonist or the GPR120 agonist is a fatty acid molecule, suitable variants and derivatives include esters thereof. Fatty acid esters can be formed with any organic compound (such as alcohol) containing a hydroxyl functional group. Esters formed by glycerol include monoglycerides, diglycerides and triglycerides. Therefore, the esters mentioned herein include corresponding monoglycerides, diglycerides and triglycerides of the relevant fatty acids or molecules. The agonist can be a complete or partial agonist.
[0014] GPR84 agonists include: medium-chain free fatty acids (FFA) with carbon chain lengths of C9 to C14, such as lauric acid (C12:0), nonanoic acid (C9:0), capric acid (C10:0), undecanoic acid (C11:0), tridecanoic acid (C13:0) and myristic acid (C14:0), or their esters; and other compounds, such as 3,3'-diindolylmethane (also known as 3,3'-methanediylbis(1H-indole)).
[0015] In one embodiment, the GPR84 agonist is selected from lauric acid (C12:0), undecanoic acid (C11:0) and capric acid (C10:0), or an ester thereof. Suitably, the GPR84 agonist is lauric acid.
[0016] Other GPR84 agonists include 2-pentylthiopyrimidine-4,6-diol, 6-nonylpyridine-2,4-diol, anthracene (undecyl-1,4-benzoquinone) or its esters. Liu et al ACS Med. Chem. Lett. 30 March 2016 (DOI: 10.1021 / acsmedchemlett.6b00025) described a series of 2-alkylpyrimidine-4,6-diol derivatives.
[0017] GPR120 agonists include ω-3 fatty acids, or esters thereof and other analog compounds, such as [3-(4-((4-fluoro-4'-methyl-[1,1'-biphenyl]-2-yl)methoxy)phenyl)propionic acid (TUG891) or its esters. ω-3 fatty acids are polyunsaturated fatty acids (PUFAs), such as α-linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), or their esters.
[0018] α-linolenic acid (ALA) contains three unsaturated carbon-carbon double bonds (n-3) and is also called (9Z,12Z,15Z)-9,12,15-octadecatrienoic acid or cis,cis,cis-9,12,15-octadecatrienoic acid. α-linolenic acid (ALA) is sometimes also called 18:3.
[0019] Eicosapentaenoic acid (EPA) (or eicosapentaenoic acid) is sometimes referred to as 20:5(n-3). The formal name of the molecule is (5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-eicosapentaenoic acid.
[0020] Docosahexaenoic acid (DHA) is also known as (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid and contains six unsaturated carbon-carbon double bonds 22:6 (n-3).
[0021] Other GPR120 agonists include 4-methoxy-N-(2,4,6-trimethylphenyl)benzenesulfonamide, 4-(4-{2-[phenyl(pyridin-2-yl)amino]ethoxy}phenyl)butanoic acid, 3-(4-((4-fluoro-4'-methyl-(1,1'-biphenyl)-2-yl)methoxy)-phenyl)propanoic acid (Oh Nature Medicine, 20(8)942-949(2014)) and folate or its esters. Other GP120 agonists are disclosed in WO 2015 / 134039, which describes a class of isothiazole derivatives (see also Abdel-Magid ACSMed.Chem.Lett., 6, 1097-1098(2015)) or their esters.
[0022] The GPR120 agonist may be derived from a natural (non-synthetic) source, such as a plant seed, suitably in the form of an oil prepared from the seed (ie, a plant seed oil). Alternatively, the GPR120 agonist may be synthesized using chemical or biological means.
[0023] Suitably, the natural source of oil contains at least 50% ALA, or at least 60%, 65% or 70% ALA. Examples of suitable plant seed oils are linseed oil and chia seed oil. An example of linseed oil contains 68.2% ALA (Segura-Campos et al., Int J Food Sci, 2014).
[0024] Flaxseed oil, also known as linseed oil, is obtained from the dried mature seeds of the flax plant. Flaxseed oil mainly contains the unsaturated fatty acids alpha-linolenic acid, linoleic acid, and oleic acid. For example, the amount of alpha-linolenic acid may be 50% to 75%, the amount of linoleic acid may be 10% to 25%, and the amount of oleic acid may be 10% to 35%.
[0025] For example, linseed oil may contain 53.21% alpha-linolenic acid, 17.25% linoleic acid, and 18.51% oleic acid.
[0026] GPR120 may also be referred to as free fatty acid receptor 4 (FFA4) or (FFA4 / GPR120).
[0027] In another embodiment of the present invention, the composition may comprise a plurality of GPR84 agonists and GPR120 agonists. Suitably, the composition may comprise a pair of GPR84 agonists and GPR120 agonists. For example, the composition may comprise 3,3'-diindolylmethane / lauric acid (DIM / LA) and alpha-linolenic acid (ALA).
[0028] The composition of the present invention upregulates the phosphorylated form of extracellular signal-regulated kinase (pERK) and the phosphorylated form of calmodulin kinase (pCaMKII), thereby increasing the number of activated cells compared to a single treatment with a single agonist alone. Thus, the combined formulation is able to maximize the activation of L cells and EC cells in human intestinal tissue.
[0029] L cells are a specialized form of enteroendocrine cell that secretes glucagon-like peptide-1 (GLP-1), peptide YY (PYY), oxyntomodulin, and glucagon-like peptide-2 (GLP-2). EC cells are enterochromaffin cells or "Kulchetsky cells" that release serotonin.
[0030] The composition of the present invention comprising a GPR84 agonist and a GPR120 agonist can be formulated according to convenience for administration to a patient in need thereof.
[0031] The composition of the present invention can be provided in the form of a pharmaceutical composition. The composition can be prepared into liquid, solid or powder according to convenience.
[0032] The pharmaceutical composition can be administered in a manner that is effective and convenient for effectively treating obesity, including, for example, oral, nasogastric, rectal, intraperitoneal or intravenous, or other routes of administration. It is contemplated that the composition of the present invention will find the best use as an orally administrable formulation or as a suppository. The composition can also be administered to an individual as a liquid composition, for example, as a sterile dispersion for administration via a nasogastric tube or stoma.
[0033] Compositions can be formulated as needed with these other salts, preservatives and stabilizers and / or excipients or adjuvants. For example, amino acids can be present in the formulation. Amino acids can be selected from one or more of the following: glycine, alanine, valine, leucine, isoleucine, serine, cysteine, selenocysteine, threonine, methionine, proline, phenylalanine, tyrosine, tryptophan, histidine, lysine, arginine, aspartic acid, glutamic acid, asparagine and glutamine. The example of preservative is vitamin E, including its isomers and derivatives, such as alpha-tocopherol, gamma-tocopherol, d-alpha-tocopherol succinate.
[0034] The formulation may be provided in a capsule, for example in a delayed release capsule, wherein suitably the capsule will only disintegrate upon reaching the large or terminal part of the small intestine. Suitably, the delayed release capsule is a colon release capsule wherein the contents are preferentially released in the colon.
[0035] Such capsules can be administered before a meal, for example about 30 minutes before a meal. Suitable delayed release capsules can be prepared using anionic polymers of suitable monomers that preferably degrade at a pH of 7.0 or higher. Examples of such suitable monomers are methacrylic acid and methyl methacrylate (for example available from Evonik Industries under the trade name (sold as methacrylic acid). Thus, the capsule may consist of a polymer of methacrylic acid and methyl methacrylate.
[0036] Such capsules can be designed to release sufficient fatty acids to achieve intraluminal local concentrations of >25 mmol / L, which has been shown to be optimal for stimulation of enteroendocrine cells and subsequent release of gut satiety hormones.
[0037] Alternatively, the composition may be formulated as an emulsion, suitably in the presence of an emulsifier or with starch.
[0038] In one embodiment, a liquid formulation of lauric acid and alpha-linolenic acid is provided.
[0039] The powder form of the composition can be prepared into the form of tablets, small tablets, pills or granules (usually filled in capsule shells) for oral administration. Tablets can be coated with suitable enteric coatings to be released in the small intestine by the patient's stomach. Suitable enteric coatings include but are not limited to methyl acrylate-methacrylic acid copolymers, cellulose acetate phthalate (CAP), cellulose acetate succinate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate (hydroxypropyl methylcellulose acetate succinate), polyvinyl acetate phthalate (PVAP), methyl methacrylate-methacrylic acid copolymers, shellac, cellulose acetate trimellitate, alginate (such as sodium alginate), zein (corn protein).
[0040] The GPR84 agonist and the GPR120 agonist may be administered separately, sequentially or simultaneously.According to a second aspect of the present invention, there is provided a composition comprising a GPR84 agonist and a GPR120 agonist as a combined formulation for simultaneous, separate or sequential use in the treatment of obesity and overweight.
[0041] As used herein, the term "treatment" includes any regime that can benefit a human or non-human animal. Treatment of "non-human animals" extends to treatment of livestock, including horses and companion animals (e.g., cats and dogs), and farm / agricultural animals, including sheep, goats, pigs, cattle, and members of the equine family.
[0042] According to the present invention, treatment of obesity includes prophylactic (preventative) treatment of patients at risk for the condition, as well as curative treatment of patients already suffering from obesity and overweight.
[0043] For administration to mammals, particularly humans, it is contemplated that the daily dosage range for the GPR84 agonist is from about 1000 mg to about 5000 mg per day, optionally from about 1500 mg to about 3000 mg per day, for example about 1000 mg per day or about 2000 mg per day, and the range for the GPR120 agonist is from about 100 mg to 5000 mg per day, optionally from about 150 mg to about 2000 mg per day, for example about 1000 mg per day.
[0044] When a pair of GPR84 agonists is present in the composition, the amount of the second GPR84 agonist may be from 50 mg to 300 mg.
[0045] Thus, suitable dosage forms may be prepared at doses of 100 mg, 150 mg, 1000 mg, 1500 mg, 2000 mg, 3000 mg or 5000 mg.
[0046] In one embodiment, the present invention provides a delayed release formulation specifically for the distal small and large intestine. Preparations (e.g. S100), the delayed release The formulation contains a mixture of fatty acids and amino acids, for example 1000 mg lauric acid and 1000 mg alpha-linolenic acid, or about 2000 mg lauric acid and 1000 mg alpha-linolenic acid.
[0047] In any case, the doctor will determine the actual dosage that is most suitable for the individual, which will depend on factors including the individual's age, weight, sex and response. The above dosages are examples of average situations. Of course, there may be situations where higher or lower dosages may be appropriate, and these are within the scope of the present invention.
[0048] The frequency of dosage can be varied as desired, but it may be appropriate to administer the composition before a meal is eaten. The composition may be administered up to 90 minutes before a meal is eaten, up to 60 minutes before a meal, or up to 30 minutes before a meal. The composition may be administered before two standard meals separated by up to 4 hours.
[0049] In one dosage regimen, 2 capsules as defined above (eg 1000 mg lauric acid and 1000 mg alpha-linolenic acid, or 2000 mg lauric acid and 1000 mg alpha-linolenic acid) may be taken 30 minutes before the patient consumes a meal.
[0050] In the case of flaxseed oil as a source of the GPR120 agonist, the dosage may be 500 mg to 5000 mg per day.
[0051] According to a third aspect of the present invention, there is provided a method of treating obesity and overweight, said method comprising the step of administering a composition as defined above to a patient in need thereof. Accordingly, the present invention extends to such a composition for use in treating obesity and overweight.
[0052] According to a fourth aspect of the present invention, there is provided use of a GPR84 agonist and a GPR120 agonist in the preparation of a medicament for treating obesity and overweight.
[0053] The World Health Organization (WHO) defines obesity as abnormal or excessive fat accumulation that may impair health, with a body mass index (BMI) greater than or equal to 30 defining obesity.
[0054] The World Health Organization (WHO) defines overweight as abnormal or excessive fat accumulation that may impair health, with a body mass index (BMI) greater than or equal to 25 being considered overweight.
[0055] Body mass index (BMI) is an indicator of weight for height that can be used to classify overweight and obesity in adults. BMI is defined as a person's weight in kilograms divided by the square of his or her height in meters (kg / m 2 ).
[0056] According to a fifth aspect of the present invention, a kit is provided, comprising a GPR84 agonist and a GPR120 agonist and optionally a dosing carrier and / or instructions for use.
[0057] Without wishing to be bound by theory, it is believed that the present invention overcomes problems encountered in previous approaches because it simultaneously activates two parallel satiety pathways.
[0058] It appears that GPR84 and GPR120 colocalize on human enteroendocrine cells, and coactivation of the two results in super additive activation of pERK and pCAMKII. This means that the intestinal hormone response seen after gastric bypass surgery can be enhanced, which cannot be achieved using one stimulus alone (Ma et al. Diabetologia 56: 1236-42 (2013)).
[0059] The present invention provides a combination of nutrients to achieve superadditive activation of the enteroendocrine response. Formulations can be prepared to deliver only to the distal intestine. The compositions of the present invention provide reduced doses of therapeutic agents. The present invention can achieve these advantages through a composition that is administered as a capsule and contains a minimal caloric load but maximizes satiety by acting on the lower intestine.
[0060] The present invention may find significant use in individuals who wish to lose weight without intestinal disease.
[0061] Exemplary formulations may include:
[0062] LA / ALA preparations
[0063] Lauric acid - 1500mg to about 3000mg
[0064] Alpha-linolenic acid - 150mg to about 2000mg
[0065] Vitamin E - 1 to 5%
[0066] DIM / ALA preparations
[0067] 3,3'-Diindolylmethane - 100mg to about 250mg
[0068] Alpha-linolenic acid - 150mg to about 2000mg
[0069] Vitamin E - 1 to 5%
[0070] DIM / ALA preparations
[0071] 3,3'-Diindolylmethane - 50mg to about 300mg
[0072] Alpha-linolenic acid - 150mg to about 2000mg
[0073] Vitamin E - 1 to 5%
[0074] LA / DIM / ALA preparations
[0075] Lauric acid - 1500mg to about 3000mg
[0076] 3,3'-Diindolylmethane - 50mg to about 300mg
[0077] Alpha-linolenic acid - 150mg to about 2000mg
[0078] Vitamin E - 1 to 5%
[0079] Flaxseed Oil / ALA Preparations
[0080] Flaxseed oil – 500mg to approximately 5000mg
[0081] Alpha-linolenic acid - 150mg to about 2000mg
[0082] Vitamin E - 1 to 5%
[0083] Suitably, the formulation is encapsulated in a capsule composed of a polymer of methacrylic acid and methyl methacrylate monomers.
[0084] Preferred features of the second and subsequent aspects of the invention are as for the first aspect mutatis mutandis. BRIEF DESCRIPTION OF THE DRAWINGS
[0085] The present invention will now be further described by way of illustration with reference to the following examples and figures, in which:
[0086] Figure 1 L cells are shown to co-express GPR120 and GPR84.
[0087] Figure 2 Enterochromaffin cells are shown to co-express GPR120 and GPR84.
[0088] Figure 3 GPR84 and GPR120 were shown to be expressed primarily on 5-HT-containing EC cells, albeit to a lesser extent, along with L cells.
[0089] Figure 4Shown: Upper panel - TUG891 significantly increased cell activation as measured by expression of 10 μM pCAMKII compared to control (N=3, p<0.05). Lower panel - 5-HT positive cells were activated after stimulation with TUG891 as shown in the merged image.
[0090] Figure 5 It was shown that stimulation of the human proximal colon with a combination of LA and TUG891 significantly increased the activation of pERK and pCamKII, indicating an overall increase in activation of colonic epithelial cells (N=3, n=15, p<0.05).
[0091] Figure 6 The synergistic effect of the composition of the present invention is shown in (a) compared with the control, with 12.5 mmol -1 and 25mmol -1 Cell activation when lauric acid (LA) was administered alone; (b) cell activation when TUG891 was administered alone at 1 μM and 10 μM compared to control; and (c) cell activation when TUG891 was administered alone at 25 mmol / L and 10 μM compared to control. -1 Compared with LA or 10 μM TUG891 alone, LA plus TUG891 (25 mmol -1 Cell activation when LA and 10 μM TUG891) were administered in combination.
[0092] Figure 7 Shown are hormone release profiles of PYY and GLP-1 from cells for the composition of the present invention using lauric acid (LA) and TUG891 (TUG).
[0093] Figure 8 The GPR84 agonist 3,3'-diindolylmethane (DIM) was shown to potently activate pERK in combination with the GPR120 agonist TUG891 and the GPR84 agonist lauric acid.
[0094] Fig. 9 The naturally occurring GPR120 agonists α-linolenic acid (ALA) and flaxseed oil are shown to potently induce the expression of cell activation markers pCamKii and pERK in human colonic mucosa. (a) Both ALA and flaxseed oil activate colonocytes through pCamKii activation, with most of the positive staining in the apical region of the cells. In the enlarged inset image, arrows point to highlighted positive cells. (b) Upon stimulation with ALA and flaxseed oil, a large number of colonocytes are positive for pERK, as indicated by white stars. DETAILED DESCRIPTION
[0095] Example 1: Nutrition The chromatin receptors GPR120 and GPR84 are expressed in L cells (containing GLP-1) and enterochromaffin cells (containing 5- Co-expression on HT
[0096] Triple stain immunohistochemistry of human proximal colon was used to examine co-expression of the nutrient receptors GPR120 and GPR84 on L cells (containing GLP-1) and enterochromaffin cells (containing 5-HT). Figure 1 Both receptors are shown to be expressed on the basolateral side of L cells (red). Figure 2 Enterochromaffin cells (green) are shown to express both receptors at the cell periphery, including long processes that extend into the lumen and come into direct contact with nutrients available in the lumen. Both GPR84 and GPR120 were found to be highly expressed in enterochromaffin cells (ECs) containing 5-HT, in addition to being expressed on L cells (which have GLP-1 and PYY). Figure 3 ).
[0097] Example 2: GPR120 agonists preferentially activate distinct intracellular pathways driven by phosphorylated CaMKII
[0098] It has been shown previously (Symonds, Peiris, et al, Gut 2014) that stimulation of human colonic mucosa with lauric acid (GPR84 agonist) activates intracellular pathways as measured by phosphorylated ERK. The present results show that TUG891 (GPR120 agonist) preferentially activates different intracellular pathways driven by phosphorylated CaMKII, with some of the activated cells identified as EC cells ( Figure 4 ).
[0099] Example 3: Combined formulation for activation of L cells and EC cells in human proximal colon slices
[0100] The present results also showed that both pERK and pCaMKII were upregulated, demonstrating that the combination of nutrients could increase the number of activated cells compared with single nutrient treatment ( Figure 6 Importantly, when stimulated in human proximal colon slices with the combined formulation of lauric acid and TUG891, the increased number of activated L cells was able to maximally release their contents, namely the hormones GLP-1 and PYY ( Figure 7 ).
[0101] Example 4: Patient Trials of Formulations
[0102] The compositions of the invention were tested in patients according to the following protocol.
[0103] Stage I Acute
[0104] Purpose : Testing the effects of a sustained-release capsule of a combination of nutrients on metabolic parameters in obese patients with type 2 diabetes
[0105] design: A randomized double-blind placebo-controlled crossover study in 20 overweight volunteers. (1g, 2g and 5g doses, 60 minutes before 2 standard meals 4 hours apart, 2 weeks between trials)
[0106] result :
[0107] Postprandial satiety questionnaire, plasma gut hormones, 5-HT, glucose and insulin profiles
[0108] Stage II Chronic
[0109] type :Phase IIb.
[0110] Purpose : Testing the effects of a sustained-release capsule of a combination of nutrients on weight loss and blood sugar control
[0111] design : A randomized, double-blind, placebo-controlled, parallel trial with 20 overweight volunteers. (Dosing will be based on data obtained from the Phase 1 trial 60 minutes before twice daily meals). There will be no run-in or wash-out period.
[0112] result :
[0113] 1°- Weight loss after 24 weeks of medication
[0114] 2°-Body fat mass, glycosylated hemoglobin (HbA1c), fasting blood glucose concentration (BGC).
[0115] Example 5: GPR84 agonist 3,3'-diindolylmethane (DIM) and GPR120 agonists TUG891 and GPR84 The agonist lauric acid combination potently activated pERK.
[0116] The results showed that the GPR84 agonist 3,3'-diindolylmethane (DIM) had a positive effect on the GPR120 agonist TUG891 and the GPR84 agonist lauric acid when administered in combination. force Activates an intracellular pathway driven by phosphorylated ERK in colon cells ( Figure 8 ).
[0117] Example 6: 100 mM ALA and flaxseed oil activate intracellular signaling driven by phosphorylated ERK and phosphorylated CaMKII path.
[0118] The naturally occurring GPR120 agonists ALA and flaxseed oil activated the intracellular pathway as measured by phosphorylated ERK and phosphorylated CaMKII in human colonic mucosa. ALA and flaxseed oil have high affinity for GPR120, but are also recognized by GPR84. Compared to the selective GPR120 agonist TUG891, which only activates phosphorylated CaMKII, ALA and flaxseed oil activated phosphorylated ERK and phosphorylated CaMKII (see Example 2) ( Figure 8 ).
Claims
1. Use of a pharmaceutical composition comprising a GPR84 agonist and a GPR120 agonist in the preparation of a medicament for treating obesity and overweight, wherein the GPR84 agonist is selected from the group consisting of lauric acid, 3,3'-diindolylmethane, and a combination thereof; and wherein the GPR120 agonist is selected from the group consisting of α-linolenic acid, [3-(4-((4-fluoro-4'-methyl-[1,1'-biphenyl]-2-yl)methoxy)phenyl)propionic acid and a combination thereof; and The drug is a colon release capsule preparation.
2. The use according to claim 1, characterized in that The GPR84 agonist is lauric acid.
3. The use according to claim 1, characterized in that The GPR120 agonist is α-linolenic acid.
4. The use according to claim 1, characterized in that The GPR120 agonist is [3-(4-((4-fluoro-4'-methyl-[1,1'-biphenyl]-2-yl)methoxy)phenyl)propanoic acid.
5. The use according to claim 1, characterized in that: The composition includes a pair of a GPR84 agonist and a GPR120 agonist.
6. The use according to claim 5, characterized in that The pair of GPR84 agonists is lauric acid and 3,3'-diindolylmethane and the GPR120 agonist is alpha-linolenic acid.
7. The use according to claim 1, characterized in that The GPR120 agonist is derived from a natural source.
8. The use according to claim 7, characterized in that The natural source of the GPR120 agonist is plant seed oil.
9. The use according to claim 8, characterized in that The vegetable seed oil is linseed oil.
10. The use according to claim 1, characterized in that The composition also comprises amino acids.
11. The use according to claim 1, characterized in that The medicament comprises a GPR84 agonist and a GPR120 agonist as a combined formulation for simultaneous, separate or sequential use in the treatment of obesity and overweight.
